Results 151 to 160 of about 49,940 (198)
Assessment of adalimumab used in a patient with hemorrhagic rheumatoid neutrophilic dermatosis. [PDF]
Postepy Dermatol AlergolWei T, Duan Z, Chen H, Xiang Z, Li CR.
europepmc +1 more source
Exploring the therapeutic effects of intensified immunosuppressive regimen for preengraftment syndrome after umbilical cord blood transplantation. [PDF]
Clin Exp MedLiu D +8 more
europepmc +1 more source
Optimising Therapeutic Intervals for Anti-TNF Biologics in Rheumatoid Arthritis: A Retrospective Real-World Study. [PDF]
Life (Basel)Dodero-Anillo JM +2 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Biological Therapy, 2008
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
+7 more sources
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
+7 more sources
Annales de Dermatologie et de Vénéréologie, 2005
Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p.
+5 more sources
Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p.
+5 more sources
Expert Review of Clinical Immunology, 2005
Etanercept is a member of a new generation of therapeutic agents referred to as biologics or targeted therapies, which have caused some enthusiasm in the field of autoimmune disorders in recent years. Most of these agents are inhibitors of tumor necrosis factor, a key cytokine in the chronic inflammatory process.
Mathias, Grunke, Joachim Robert, Kalden
openaire +2 more sources
Etanercept is a member of a new generation of therapeutic agents referred to as biologics or targeted therapies, which have caused some enthusiasm in the field of autoimmune disorders in recent years. Most of these agents are inhibitors of tumor necrosis factor, a key cytokine in the chronic inflammatory process.
Mathias, Grunke, Joachim Robert, Kalden
openaire +2 more sources
Journal of the American Academy of Dermatology, 2003
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Ben, Goffe, Jennifer Clay, Cather
openaire +2 more sources
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Ben, Goffe, Jennifer Clay, Cather
openaire +2 more sources
BioDrugs, 2004
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire +2 more sources
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire +2 more sources